NEW YORK – Singapore-based genomic medicine startup Lucence Diagnostics plans to enter the US cancer market by building a laboratory in Silicon Valley and subsequently launching its LiquidHallmark late-stage lung cancer treatment selection next-generation sequencing assay in the second half of 2020.
The firm also presented the results of a validation study earlier this month, applying the error-correction sequencing amplicon-based platform in hematological cancers.